Fetal Pancreas Transplantation for Treatment of Type I Diabetes: Miniature Swine Model

  • Yoko Mullen
Chapter

Abstract

Transplantation of insulin-producing cells has emerged as the most promising new approach for the treatment of Type I diabetes mellitus. Current treatment based on daily insulin injections does not completely control hyperglycemia, nor does it prevent the complications associated with diabetes. In the early 1970s, Dr. Josiah Brown organized a small research group at UCLA to investigate the feasibility of using fetal pancreata as the donor tissue for transplantation. The idea was supported by previous studies in mice by Browning and Resnick in 1952 (1) and in rats by Coupland in 1960 (2). These studies demonstrated that fetal pancreas tissue transplanted into the anterior chamber of the eye grew and differentiated progressively with good vascularization. The growth was limited to endocrine elements, while exocrine elements atrophied. Initially, our studies used inbred strains of rats to determine the various factors involved in transplantation. The reversal of streptozotocin (SZN) diabetes in Lewis strain rats by fetal pancreas transplants was first reported by our group in 1974 (3).

Keywords

Transplant Proc Donor Tissue Allograft Survival Mixed Lymphocyte Culture Fetal Pancreas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Browning H, Resnick P: Homologus and heterologous transplantation of pancreatic tissue in normal and diabetic mice. Yale J Biol Med 1952; 24:141–152.CrossRefGoogle Scholar
  2. 2.
    Coupland RE: The survival and growth of pancreatic tissue in the anterior chamber of the eye of the albino rat. J Endocrinol 1960; 20:69–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Brown J, Molnar IG, Clark WR, Mullen Y: Control of experimental diabetes in rats by transplantation of fetal pancreases. Science 1974; 184:1377–1379.PubMedCrossRefGoogle Scholar
  4. 4.
    Brown J, Clark WR, Molnar IG, Mullen Y: Fetal pancreas transplantation for reversal of streptozotocin induced diabetes in rats. Diabetes 1976; 25:56–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Clark WR, Rutter WJ: Synthesis and accumulation of insulin in the fetal rat pancreas. Dev Biol 1972; 29:468–481.PubMedCrossRefGoogle Scholar
  6. 6.
    Pictet RL, Clark WR, Williams RH, Rutter WJ: An ultrastructural analysis of the developing embryonic pancreas. Dev Biol 1972; 29:436–467.PubMedCrossRefGoogle Scholar
  7. 7.
    Mullen Y, Clark WR, Molnar IG, Brown J: Complete reversal of experimental diabetes mellitus in rats by a single fetal pancreas. Science 1977; 195:68–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Yokoyama J, Brown J, Mullen Y: Glucagon culture prevents acinar cell growth in older fetal pancreas grafts. Diabetes 1984; (suppl 1):181A.Google Scholar
  9. 9.
    Field JB: Insulin extraction by the liver. In Greep RO, Astwood EB (eds): Vol I: Handbook of Physiology Section 7, Endocrinology American Physiology Society, Washington DC, 1972, p 505–513.Google Scholar
  10. 10.
    Brown J, Mullen Y, Clark WR, et al: Importance of hepatic portal circulation for insulin action in streptozotocin-diabetic rats transplanted with fetal pancreases. J Clin Invest 1979; 64:1688–1694.PubMedCrossRefGoogle Scholar
  11. 11.
    Mullen Y, Clark WR, Kemp J, et al: Reversal of experimental diabetes by fetal rat pancreases. II. Critical procedures for transplantation. Transplant Proc 1977; 9:325–328.PubMedGoogle Scholar
  12. 12.
    Weisman H, Mullen Y, Brown J: Insulin release during perfusion from fetal pancreases transplanted into normal and diabetic animals. Diabetes 1980; 29:566–570.PubMedGoogle Scholar
  13. 13.
    Brown J, Heininger D, Kuret J, Mullen Y: Islet cells grow after transplantation of fetal pancreas and control of diabetes. Diabetes 1981; 30:9–13.PubMedGoogle Scholar
  14. 14.
    Brown J, Heininger D, Kuret J, Mullen Y: Normal response to pregnancy in rats cured of streptozotocin diabetes by transplantation of one fetal pancreas. Diabetologia 1982; 22:273–275.PubMedCrossRefGoogle Scholar
  15. 15.
    Makoff RK, Brown J, Mullen Y, Clark R: Normalization of six key hepatic enzymes after fetal pancreas transplantation in diabetic rats. Diabetes 1983; 32:730–733.PubMedCrossRefGoogle Scholar
  16. 16.
    Inoue S, Kajinuma H, Morita T, Mullen Y: Restoration of insulin and glucagon release by fetal pancreatic transplantation in diabetic rats, in Sakamoto N, Alberti KGMM (eds): Current and Future Therapies with Insulin. Amsterdam, Excerpta Medica, 1983; pp 384–389.Google Scholar
  17. 17.
    Mazur P, Kemp J, Miller RH: Survival of fetal rat pancreas frozen to-78° and — 196°C. Proc Natl Acad Sci 1976; 73:4105–4109.PubMedCrossRefGoogle Scholar
  18. 18.
    Kemp J, Mazur P, Mullen Y, et al: Reversal of experimental diabetes by fetal rat pancreases. II. Survival and function of fetal rat pancreases frozen to — 196°C. Transplant Proc 1977; 9:329–332.PubMedGoogle Scholar
  19. 19.
    Kemp J, Mullen Y, Weisman H, et al: Reversal of diabetes in rats using fetal pancreases stored at — 196°C. Transplantation 1978; 26:260–264.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown J, Kemp J, Hurt S, Clark WR: Cryopreservation of human fetal pancreas. Diabetes 1980; 29(suppl 1):70–73.PubMedGoogle Scholar
  21. 21.
    Kemp J, Hurt S, Brown J, Clark WR: Recovery and function of human fetal pancreas frozen to — 196°C. Transplantation 1981; 32:10–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown J, Clark WR, Mullen Y: Cryopreservation of the fetal pancreas, rat, pig, human, in Larner J, Pohl SL (eds): Methods in Diabetes Research, Vol. I: Laboratory Methods, Part C. John Wiley & Sons Inc, New York, 1984, pp 318–324.Google Scholar
  23. 23.
    Shiogama T, Mullen Y, Klandorf H, et al: Improved cryopreservation procedure for human fetal pancreas tissues. Transplantation (in press).Google Scholar
  24. 24.
    Mullen Y, Shintaku PI: Fetal pancreas allografts for reversal of diabetes in rats. I. Allograft survivals in non-immunosuppressed recipients. Transplantation 1980; 29:35–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Mullen Y, Shibukawa RL: Use of TLI in rat fetal pancreas transplantation. Diabetes 1982; 31(suppl 1):69–74.PubMedGoogle Scholar
  26. 26.
    Mullen Y, Gottlieb M, Shibukawa RL: Reversal of diabetes in rats by fetal pancreas allografts following TLI. Transplant Proc 1983; 15:1355–1358.Google Scholar
  27. 27.
    Mullen Y: Permanent reversal of experimental diabetes in rats by allogeneic fetal pancreases across minor histocompatibility loci: Effects and characteristics of immunosuppression induced by allo-antigen, procarbazine hydrochloride, and anti-lymphocyte serum treatment. Transplant Proc 1981; 13:823–825.PubMedGoogle Scholar
  28. 28.
    Mullen Y, Shintaku PI: Fetal pancreas allografts for reversal of diabetes in rats. II. Induction of life-term specific unresponsiveness to fetal pancreas allografts across minor histocompatibility. Transplantation 1982; 33:3–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Sachs DH, Leight G, Cone J, et al: Transplantation in miniature swine. I. Fixation of the major histocompatibility complex. Transplantation 1975; 22:559–567.CrossRefGoogle Scholar
  30. 30.
    Leight GS, Sachs DH, Rosenberg SA: Transplantation in miniature swine. II. In vitro parameters of histocompatibility in MSLA homozygous minipigs. Transplantation 1977; 23:271–276.PubMedCrossRefGoogle Scholar
  31. 31.
    Pond WG, Houpt KA: The Biology of the Pig. Ithaca, Cornell University Press, 1978.Google Scholar
  32. 32.
    Sasaki N, Yoneda K, Bigger C, et al: Fetal pancreas transplantation in miniature swine. I. Developmental characteristics of fetal pig pancreases. Transplantation 1984; 38:335–340.PubMedCrossRefGoogle Scholar
  33. 33.
    Lunney JK, Osborne BA, Sharrow SO, et al: Sharing of Ia antigens between species: IV. Interspecies cross-reactivity of monoclonal antibodies directed against polymorphic Ia determinants. J Immunol 1983; 130:2786–2793.PubMedGoogle Scholar
  34. 34.
    Motojima K, Mullen Y: Fetal pancreas transplantation in miniature swine. II. Class II antigen expression in the pancreas during fetal development, to be published.Google Scholar
  35. 35.
    Danilovs JA, Hofman FM, Taylor CR, Brown J: Expression of HLA-DR antigens in human fetal pancreas tissue. Diabetes 1982; 31(suppl 1):23–28.PubMedGoogle Scholar
  36. 36.
    Fujiya H, Danilovs JA, Brown J, Mullen Y: Species difference in dendritic cell distribution in pancreas during fetal development. Transplant Proc 1985; 17:414–416.Google Scholar
  37. 37.
    Motojima K, Mullen Y: IFN-γ stimulates cryptic class II antigen expression in human and pig fetal pancreas. Transplant Proc 1987; 19:214.PubMedGoogle Scholar
  38. 38.
    Mullen Y, Yoneda K, Fujiya H, et al: Survival of cultured fetal pancreas transplants in miniature pigs. Transplant Proc 1985; 17:417–419.Google Scholar
  39. 39.
    Lacy PE, Davie JM, Finke EH: Prolongation of murine islet allograft survival following in vitro culture (24°C) and a single injection of ALS. Science 1979; 204:312–313.PubMedCrossRefGoogle Scholar
  40. 40.
    Operz G, Terasaki PI: Lymphocyte antigenicity loss with retention of responsiveness. Science 1974; 184:464–466.CrossRefGoogle Scholar
  41. 41.
    Yoneda K, Mullen Y, Ozawa A, Stein E: Viability and immunogenicity of 24°C-cultured fetal pig pancreas (to be published).Google Scholar
  42. 42.
    Faustman D, Hamptfeld V, Lacy P, Davie J: Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci USA 1981; 78:5156–5159.PubMedCrossRefGoogle Scholar
  43. 43.
    Faustman DL, Steinman RM, Gebel HM, et al: Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci USA 1984; 81:3864–3868.PubMedCrossRefGoogle Scholar
  44. 44.
    Bowen KM, Lafferty KJ: Reversal of diabetes by allogeneic islet transplantation without immunosuppression. Aust J Exp Biol Med Sci 1980; 58:441–447.PubMedCrossRefGoogle Scholar
  45. 45.
    Sizuru JA, Hunt T, Fathman CG, Merrell RC: Ricin-toxin conjugated anti-Ia monoclonal antibody in the elimination of class II antigen bearing cells in islets. Diabetes 1984; 33(Suppl 1):62A.Google Scholar
  46. 46.
    Mullen Y, Shiogama T, Ozawa A, et al: Immunogenicity and viability of anti-class II immuno-toxin-treated pig islet cells. Transplant Proc 1987; 19: 934–936.PubMedGoogle Scholar
  47. 47.
    Serie JR, Hegre OD: Allotransplantation of neonatal islets in non-immuno-suppressed normal and diabetic rats. Transplant Proc 1987; 19:962–964.PubMedGoogle Scholar
  48. 48.
    Thivolet J, Faure M, Demidem A, Mauduit G: Long-term survival and immunological tolerance of human epidermal allografts produced in culture. Transplantation 1986; 42:274–280.PubMedCrossRefGoogle Scholar
  49. 49.
    Mandrup-Poulsen T, Bendtzen K, Nielsen JH, et al: Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29:63–67.PubMedCrossRefGoogle Scholar
  50. 50.
    Sherwood RA, Brent L, Rayfield LS: MHC antigens are presented by host accessory sory cells. Transplant Proc 1987; 19:239–241.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Yoko Mullen

There are no affiliations available

Personalised recommendations